SAN DIEGO, Nov. 20, 2017 /PRNewswire/ -- Mirati
Therapeutics, Inc. (NASDAQ: MRTX) today announced the closing of
its previously announced underwritten public offering of 2,938,986
shares of its common stock at a public offering price of
$13.00 per share. This includes the
exercise in full by the underwriters of their option to purchase up
to 923,085 additional shares of common stock. In addition, and in
lieu of common stock, Mirati sold to certain investors pre-funded
warrants to purchase up to an aggregate of 4,137,999 shares of
common stock at a purchase price of $12.999 per warrant, which represents the per
share public offering price for the common stock less the
$0.001 per share exercise price for
each such pre-funded warrant. The aggregate gross proceeds to
Mirati from this offering were approximately $92.0 million, before deducting underwriting
discounts and commissions and estimated offering expenses payable
by Mirati.
Cowen and Barclays acted as joint book-running managers in the
offering. SunTrust Robinson Humphrey, Oppenheimer & Co. and
H.C. Wainwright & Co. acted as
co-lead managers in the offering.
The securities described above were offered by Mirati pursuant
to a shelf registration statement filed by Mirati with the
Securities and Exchange Commission ("SEC") that was declared
effective on November 18, 2015. A
final prospectus supplement and accompanying prospectus relating to
the offering was filed with the SEC and is available on the SEC's
website located at http://www.sec.gov. Copies of the final
prospectus supplement and the accompanying prospectus relating to
the offering may be obtained from the offices of Cowen and Company,
LLC, c/o Broadridge Financial Services, 1155 Long Island Avenue,
Edgewood, NY, 11717, Attn:
Prospectus Department, or by calling (631) 274-2806; or from
Barclays Capital Inc., c/o Broadridge Financial Solutions, 1155
Long Island Avenue, Edgewood, New
York 11717, or by telephone at (888) 603-5847, or by email
at Barclaysprospectus@broadridge.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy nor shall there be any sale of
these securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
jurisdiction.
About Mirati Therapeutics
Mirati Therapeutics is a clinical-stage biotechnology company
focused on developing a pipeline of targeted oncology products
intended to treat specific genetic and epigenetic drivers of
cancer. This approach is transforming the treatment of patients by
targeting the genetic changes in tumor cells that result in
uncontrolled tumor growth and migration. Mirati's precision
oncology programs seek to treat the patients most likely to benefit
from targeted oncology treatments and are driven by drugs that
target very specific genetic mutations, directed by genomic tests
that identify patients who carry those driver mutations. Mirati's
immuno-oncology programs are novel small molecule drugs designed to
enhance and expand the efficacy of checkpoint inhibitors when given
in combination. In addition to its clinical programs, Mirati has
active discovery research efforts focused on novel oncology
targets. The promise of these approaches includes potentially
better patient outcomes, more efficient cancer treatment and faster
drug development.
View original content with
multimedia:http://www.prnewswire.com/news-releases/mirati-therapeutics-announces-closing-of-public-offering-of-common-stock-and-full-exercise-of-underwriters-option-to-purchase-additional-shares-300559683.html
SOURCE Mirati Therapeutics, Inc.